Generating cells derived from human induced pluripotent stem cells for more reliable, more robust, and more human models of disease.
Research needs physiologically relevant, reliable, and scalable in vitro models for screening, safety, and discovery. We deliver these models through cells derived from human induced pluripotent stem cells (hiPSCs).
Over the last decade, development groups at Axol have gained an international reputation for the production and characterization of ‘excitable’ cells. These include CiPA-validated cardiomyocytes, widely used in drug safety screening, and neural stem cells from patients with neurological conditions including Alzheimer’s disease and Parkinson’s disease, both primary areas for pharmaceutical development. Axol Bioscience also generate astrocytes, microglia, and motor neurons.
Axol Bioscience was founded in 2013 by Jonathan Milner and Yichen Shi. Since the merger with Censo Biotechnologies in 2021 the company has evolved to offer custom in-house laboratory services to support biotech and pharma and a read-to-sequence library of cells and supporting media and reagents.
Axol operates under ISO 9001:2015 certification and has an open culture of collaboration and endeavor to support the future of human research.